Temporal and dose dependence of T2 and ADC at 9.4 T in a mouse model following single fraction radiation therapy

Medical Physics

Volumn 36, Issue 7, 2009, Pages 2948-2954

  Larocque, Matthew P ^a,b   Syme, Alasdair ^a,b   Yahya, Atiyah ^a,b   Wachowicz, Keith ^a   Allalunis Turner, Joan ^a,b   Fallone, B Gino ^a,b  

^a CROSS CANCER INSTITUTE   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

Author keywords

9.4 T MRI; ADC; Glioma; Radiation therapy; T2; Tumor response; Xenografts

Indexed keywords

MAGNETIC RESONANCE IMAGING; MAMMALS; RADIATION; RADIOTHERAPY; SURFACE DIFFUSION;

APPARENT DIFFUSION COEFFICIENT; DOSE DEPENDENCES; GLIOMA; RADIATION-INDUCED; STATISTICALLY SIGNIFICANT DIFFERENCE; TRANSVERSE RELAXATION TIME; TUMOR RESPONSE; XENOGRAFTS;

TUMORS;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER MODEL; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIFFUSION COEFFICIENT; GLIOMA; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RADIATION DOSE FRACTIONATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR XENOGRAFT; X RAY;

MUS;

EID: 67649610806     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3147258     Document Type: Article

References (34)

1. R. Damadian, " Tumor detection by nuclear magnetic resonance.," Science 0036-8075 171, 1151-1153 (1971). 10.1126/science.171.3976.1151
2. J. Elmore, K. Armstrong, C. Lehman, and S. Fletcher, " Screening for breast cancer.," J. Am. Med. Assoc. 0098-7484 293, 1245-1256 (2005). 10.1001/jama.293.10.1245
3. M. Kriege, " Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition.," N. Engl. J. Med. 0028-4793 351, 427-437 (2004). 10.1056/NEJMoa031759
4. L. DeAngelis, " Brain tumors.," N. Eng. J. Med. 344 (2), 114-123 (2001). 10.1056/NEJM200101113440207
5. S. Orel and M. Schnall, " MR imaging of the breast for the detection, diagnosis, and staging of breast cancer.," Radiology 0033-8419 220, 13-30 (2001).
6. S. Harms, " MRI in breast cancer diagnosis and treatment.," Curr. Probl. Diagn. Radiol. 25, 192-215 (1996). 10.1016/S0363-0188(96)90009-2 0363-0188
7. J. Weitz, M. Koch, J. Debus, T. Höhler, P. Galle, and M. Büchler, " Colorectal cancer.," Lancet 0140-6736 365, 153-165 (2005). 10.1016/S0140-6736(05)17706-X
8. A. Jani and S. Hellman, " Early prostate cancer: Clinical decision-making.," Lancet 0140-6736 361, 1045-1053 (2003). 10.1016/S0140-6736(03)12833-4
9. F. Coakley, A. Qayyum, and J. Kurhanewicz, " Magnetic resonance imaging and spectroscopic imaging of prostate cancer.," J. Urol. 170, S69-S76 (2003). 10.1097/01.ju.0000094958.23276.c4 0022-5347
10. T. Stanescu, H. -S. Jans, N. Pervez, P. Stavrev, and B. G. Fallone, " A study on the magnetic resonance imaging (MRI)-based radiation treatment planning of intracranial lesions.," Phys. Med. Biol. 0031-9155 53, 3579-3593 (2008). 10.1088/0031-9155/53/13/013
11. B. Ross, " Evaluation of cancer therapy using diffusion magnetic resonance imaging.," Mol. Cancer Ther. 2, 581-586 (2003). 1535-7163
12. D. Hamstra, A. Rehemtulla, and B. Ross, " Diffusion magnetic resonance imaging: A biomarker for treatment response in oncology.," J. Clin. Oncol. 0732-183X 25, 4104-4109 (2007). 10.1200/JCO.2007.11.9610
13. E. Henning, C. Azuma, C. Sotak, and K. Helmer, " Multispectral quantification of tissue types in a RIF-1 tumor model with histological validation. Part I.," Magn. Reson. Med. 0740-3194 57, 501-512 (2007). 10.1002/mrm.21161
14. M. Yezhelyev, X. Gao, Y. Xing, A. Al-Hajj, S. Nie, and R. O'Regan, " Emerging use of nanoparticles in diagnosis and treatment of breast cancer.," Lancet Oncol. 1470-2045 7, 657-667 (2006). 10.1016/S1470-2045(06) 70793-8
15. M. Zhao, D. Beauregard, L. Loizou, B. Davletov, and K. Brindle, " Non-invasive detection of apoptosis using magnetic resonance imaging and a targeted contrast agent.," Nat. Med. 1078-8956 7, 1241-1244 (2001). 10.1038/nm1101-1241
16. R. Gillies and D. Morse, " In vivo magnetic resonance spectroscopy in cancer.," Annu. Rev. Biomed. Eng. 1523-9829 7, 287-326 (2005). 10.1146/annurev.bioeng.7.060804.100411
17. Y. Sun, R. Mulkern, K. Schmidt, S. Doshi, M. Albert, N. Schmidt, M. Ziu, P. Black, R. Carrol, and M. Kieran, " Quantification of water diffusion and relaxation times of human U87 tumors in a mouse model.," NMR Biomed. 0952-3480 17, 399-404 (2004). 10.1002/nbm.894
18. O. T. Chenevert, P. McKeever, and B. Ross, " Monitoring early response of experimental brain tumors to therapy using diffusion magnetic resonance imaging.," Clin. Cancer Res. 3 1457-1466 (1997).
19. M. Zhao, J. G. Pipe, J. Bonnett, and J. L. Evelhoch, " Early detection of treatment response by diffusion-weighted H1 -NMR spectroscopy in a murine tumour in vivo.," Br. J. Cancer 0007-0920 73, 61-65 (1996).
20. T. Chenevert, L. Stegman, J. Taylor, P. Robertson, J. Greenberg, A. Rehemtulla, and B. Ross, " Diffusion magnetic resonance imaging: An early surrogate marker of therapeutic efficacy in brain tumours.," J. Natl. Cancer Inst. 0027-8874 92, 2029-2036 (2000). 10.1093/jnci/92.24.2029
21. D. Jennings, B. N. Hatton, J. Guo, J. -P. Galons, T. Trouard, N. Raghunand, J. Marshall, and R. Gillies, " Early response of prostate carcinoma xenografts to docetaxel chemotherapy monitored with diffusion MRI.," Neoplasia 1522-8002 4, 255-262 (2002). 10.1038/sj.neo.7900225
22. P. McConville, D. Hambardzumyan, J. Meger, M. Woolliscroft, A. Rehemtulla, B. Ross, and E. Holland, " Magnetic resonance imaging determination of tumor grade and early response to temozolomide in a genetically engineered mouse model of glioma.," Clin. Cancer Res. 1078-0432 13, 2897-2904 (2007). 10.1158/1078-0432.CCR-06-3058
23. Y. Roth, T. Tichler, G. Kostenich, J. Ruiz-Cabello, S. Maier, J. Cohen, A. Orenstein, and Y. Mardor, " High- b -value diffusion-weighted MR imaging for pretreatment prediction and early monitoring of tumour response to therapy in mice.," Radiology 0033-8419 232, 685-692 (2004). 10.1148/radiol. 2322030778
24. L. Stegman, A. Rehemtulla, D. Hamstra, D. Rice, S. Jonas, K. Stout, T. Chenevert, and B. Ross, " Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.," Gene Ther. 0969-7128 7, 1005-1010 (2000). 10.1038/sj.gt.3301199
25. V. Schepkin, T. Chenevert, K. Kuszpit, K. Lee, C. Meyer, T. Johnson, A. Rehemtulla, and B. Ross, " Sodium and proton diffusion MRI as biomarkers for early therapeutic response in subcutaneous tumors.," Magn. Reson. Imaging 0730-725X 24, 273-278 (2006). 10.1016/j.mri.2005.12.004
26. B. Moffat, T. Chenevert, T. Lawrence, C. Meyer, T. Johnson, Q. Dong, C. Tsien, S. Mukerji, D. Quint, S. Gebarski, P. Robertson, L. Junck, A. Rehemtulla, and B. Ross, " Functional diffusion map: A noninvasive MRI biomarker for early stratification of clinical brain tumor response.," Proc. Natl. Acad. Sci. U.S.A. 0027-8424 102, 5524-5529 (2005). 10.1073/pnas.0501532102
27. Y. Mardor, R. Pfeffer, R. Spiegelmann, Y. Roth, S. Maier, O. Nissim, R. Berger, A. Glicksman, J. Baram, A. Orenstein, J. Cohen, and T. Tichler, " Early detection of response to radiation therapy in patients with brain malignancies using conventional and high b-value diffusion-weighted magnetic resonance imaging.," J. Clin. Oncol. 0732-183X 21, 1094-1100 (2003). 10.1200/JCO.2003.05.069
28. K. Lee, B. Moffat, A. Schott, R. Layman, S. Ellingworth, R. Juliar, A. Khan, M. Helvie, C. Meyer, T. Chenevert, A. Rehemtulla, and B. Ross, " Prospective early response imaging biomarker for neoadjuvant breast cancer chemotherapy.," Clin. Cancer Res. 1078-0432 13, 443-450 (2007). 10.1158/1078-0432.CCR-06-1888
29. D. Hamstra, C. Galban, C. Meyer, T. Johnson, P. Sundgren, C. Tsien, T. Lawrence, L. Junck, D. Ross, A. Rehemtulla, B. Ross, and T. Chenevert, " Functional diffusion map as an early imaging biomarker for high-grade glioma: Correlation with conventional radiologic response and overall survival.," J. Clin. Oncol. 0732-183X 26, 3387-3394 (2008). 10.1200/JCO.2007.15.2363
30. E. Henning, C. Azuma, C. Sotak, and K. Helmer, " Multispectral tissue characterization in a RIF-1 tumor model: Monitoring the ADC and T2 response to single-dose radiotherapy. Part II.," Magn. Reson. Med. 0740-3194 57, 513-519 (2007). 10.1002/mrm.21178
31. A. Franko, M. Parliament, J. Allalunis-Turner, and B. Wolokoff, " Variable presence of hypoxia in M006 human glioma spheroids and in spheroids and xenografts of clonally derived sublines.," Br. J. Cancer 0007-0920 78, 1261-1268 (1998).
32. D. G. Nishimura, Principles of Magnetic Resonance Imaging (Stanford University Press, Palo Alto, CA, 1996).
33. D. Le Bihan, E. Breton, D. Lallemand, M. -L. Aubin, J. Vignaud, and M. Laval-Jeantet, " Separation of diffusion and perfusion in intravoxel incoherent motion MR imaging.," Radiology 0033-8419 168, 497-505 (1988).
34. N. Tomura, K. Narita, J. Izumi, A. Suzuki, A. Anbai, T. Otani, I. Sakuma, S. Takahashi, K. Mizoi, and J. Watarai, " Diffusion changes in a tumor and peritumoral tissue after stereotactic irradiation for brain tumors: Possible prediction of treatment response.," J. Comput. Assist. Tomogr. 0363-8715 30, 496-500 (2006). 10.1097/00004728-200605000-00024